High seroprevalence of hepatitis B virus and hepatitis C virus among human immunodeficiency virus carriers in blood donors of Burkina Faso: a need for their screening before <scp>HARRT</scp> therapy

Kirakoya‐Samadoulougou, Fati; Sanou, Mahamoudou; Samadoulougou, Sékou; Bakiono, Fidèle; Kienou, Kisito; Koumaré, Alice Kiba; Dahourou, Honorine; Kaboré, I; Ouattara, Seydou; Nébié, Yacouba; Speybroeck, Niko; Robert, Annie

doi:10.1111/jvh.12223

Cited by 4 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Report of prevalence was based on an aggregate sample size of 99,672 across all the 13-health regions of the country however mainly distributed between the two principal cities: Bobo-Dioulasso, the second main city with five (5) studies [ 27 – 31 ], and Ouagadougou, the capital city with eleven (11) studies [ 16 , 17 , 32 – 40 ]. Only two (2) published studies [ 41 , 42 ] and one unpublished study (Meda N. et al 2017 conference proceedings) where conducted on a countrywide basis. One (1) study included participants from the Boucle du Mouhoun region [ 32 ] and one (1) study included participants from the center-west region [ 15 ].…”

Section: Resultsmentioning

confidence: 99%

“…In term of population, seven (7) studies were conducted on first time voluntary blood donors [ 15 , 16 , 32 – 34 , 41 , 42 ]; Eight (8) studies were conducted on pregnant women [17, 27, 30, 32, 37–40]. A total of four (4) studies addressed HBV/HIV co-infection among HIV positive patients [ 28 , 31 , 37 , 43 ], three (3) published studies [ 16 , 29 , 35 ] and one (1) unpublished study (Meda N. et al, 2017 conference proceeding) assessed the prevalence of HBV among general population.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

High prevalence of hepatitis B infections in Burkina Faso (1996–2017): a systematic review with meta-analysis of epidemiological studies

et al. 2018

View full text Add to dashboard Cite

BackgroundHepatitis B virus (HBV) infection was long considered an important public health concern in Burkina Faso and still represents a major cause of liver cancer and cirrhosis in the active population. To counter the problem, a national strategic plan was developed and adopted in July 2017 to coordinate viral hepatitis elimination’s efforts. However evidence to support its implementation remains scanty and scattered. The main purpose of this study was to summarize available information from per-reviewed articles published over the last two decades to accurately estimate the prevalence of HBV infection in Burkina Faso.MethodsWe conducted a systematic search with meta-analysis of scientific articles using Science-Direct, Web-of-Science, PubMed/Medline, and Google Scholar. We systematically assessed all relevant publications that measured the prevalence of hepatitis B surface antigen and which were published between 1996 and 2017. We estimated the national HBV prevalence and its 95% confident interval. We subsequently adjusted the meta-analysis to possible sources of heterogeneity.ResultsWe retrieved and analyzed a total of 22 full text papers including 99,672 participants. The overall prevalence was 11.21%. The prevalence after adjustment were 9.41%, 11.11%, 11.73% and 12.61% in the general population, pregnant women, blood donors and HIV-positive persons respectively. The prevalence was higher before implementation of HBV universal vaccination and decreased from 12.80% between 1996 and 2001 to 11.11% between 2012 and 2017. The prevalence was also higher in rural area 17.35% than urban area 11.11%. The western regions were more affected with 12.69% than the central regions 10.57%. The prevalence was 14.66% in the boucle of Mouhoun region and 14.59 in the center-west region. Aggregate data were not available for the other regions.ConclusionsHBV has clearly an important burden in Burkina Faso as described by its high prevalence and this problem significantly challenges the national health care system. There is an urgent need for effective public health interventions to eliminate the problem. However, higher quality data are needed to produce reliable epidemiological estimates that will guide control efforts towards the achievement of the national strategic plan’s goals.Electronic supplementary materialThe online version of this article (10.1186/s12889-018-5432-7) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

High prevalence of hepatitis B infections in Burkina Faso (1996–2017): a systematic review with meta-analysis of epidemiological studies

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Data on HBV and HCV in West African general populations are limited. Most other reports are from specific groups such as blood donors , pregnant women , men who have sex with men and HIV‐infected individuals . Prevalence and risk factors in these specific population groups may be different from the general population.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B and C in the adult population of Bissau, Guinea‐Bissau: a cross‐sectional survey

Hønge

Olesen

Jensen

et al. 2019

Tropical Med Int Health

View full text Add to dashboard Cite

objective Hepatitis B virus (HBV) and hepatitis C virus (HCV) are prevalent in West Africa. To address the WHO 2030 goals of a 90% reduction in incidence and a 65% reduction in mortality for both infections, we assessed the prevalence of HBV and HCV from surveys in the general population.methods Participants in this cross-sectional survey were included from randomly selected houses in a demographic surveillance site in Bissau, Guinea-Bissau. Participants were interviewed and had a blood sample drawn for viral analyses (HBsAg, anti-HBs, anti-HBc, anti-HCV and HCV RNA). Risk factors of HBV and HCV infection were determined by binomial regression adjusted for sex and age.results A total of 2715 participants were included in this study. The overall HBsAg prevalence was 18.7% (95% CI: 17.3-20.2%). HBsAg was associated with male sex (adjusted risk ratio (aRR): 1.64), and prevalence decreased with age >34 years. HBV exposure was found in 91.9% of participants. Although 72.6% of individuals without sexual debut had been exposed to HBV, ever engaging in a sexual relationship was associated with higher risk of HBV exposure (aRR 1.18). The anti-HCV prevalence was 0.5% (95% CI: 0.3-0.9%), and 78.6% of those had detectable HCV RNA. Risk factors for anti-HCV sero-positivity were age above 55 (aRR 10.60), a history of blood transfusion (aRR 5.07) and being in a polygamous marriage (aRR 3.52).conclusion In Guinea-Bissau initiatives to implement treatment and widespread testing are needed to reach the WHO 2030 goals.keywords hepatitis B, hepatitis C, HIV, HIV-2, HTLV, Guinea-Bissau Sustainable Development Goals (SDGs): SDG 3 (good health and well-being), SDG 17 (partnerships for the goals)

show abstract

Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis

Platt

French

McGowan

et al. 2019

Journal of Viral Hepatitis

114

View full text Add to dashboard Cite

Globally, in 2017 35 million people were living with HIV (PLHIV) and 257 million had chronic HBV infection (HBsAg positive). The extent of HIV‐HBsAg co‐infection is unknown. We undertook a systematic review to estimate the global burden of HBsAg co‐infection in PLHIV. We searched MEDLINE, Embase and other databases for published studies (2002‐2018) measuring prevalence of HBsAg among PLHIV. The review was registered with PROSPERO (#CRD42019123388). Populations were categorized by HIV‐exposure category. The global burden of co‐infection was estimated by applying regional co‐infection prevalence estimates to UNAIDS estimates of PLHIV. We conducted a meta‐analysis to estimate the odds of HBsAg among PLHIV compared to HIV‐negative individuals. We identified 506 estimates (475 studies) of HIV‐HBsAg co‐infection prevalence from 80/195 (41.0%) countries. Globally, the prevalence of HIV‐HBsAg co‐infection is 7.6% (IQR 5.6%‐12.1%) in PLHIV, or 2.7 million HIV‐HBsAg co‐infections (IQR 2.0‐4.2). The greatest burden (69% of cases; 1.9 million) is in sub‐Saharan Africa. Globally, there was little difference in prevalence of HIV‐HBsAg co‐infection by population group (approximately 6%‐7%), but it was slightly higher among people who inject drugs (11.8% IQR 6.0%‐16.9%). Odds of HBsAg infection were 1.4 times higher among PLHIV compared to HIV‐negative individuals. There is therefore, a high global burden of HIV‐HBsAg co‐infection, especially in sub‐Saharan Africa. Key prevention strategies include infant HBV vaccination, including a timely birth‐dose. Findings also highlight the importance of targeting PLHIV, especially high‐risk groups for testing, catch‐up HBV vaccination and other preventative interventions. The global scale‐up of antiretroviral therapy (ART) for PLHIV using a tenofovir‐based ART regimen provides an opportunity to simultaneously treat those with HBV co‐infection, and in pregnant women to also reduce mother‐to‐child transmission of HBV alongside HIV.

show abstract

High seroprevalence of hepatitis B virus and hepatitis C virus among human immunodeficiency virus carriers in blood donors of Burkina Faso: a need for their screening before HARRT therapy

Cited by 4 publications

References 2 publications

High prevalence of hepatitis B infections in Burkina Faso (1996–2017): a systematic review with meta-analysis of epidemiological studies

High prevalence of hepatitis B infections in Burkina Faso (1996–2017): a systematic review with meta-analysis of epidemiological studies

Hepatitis B and C in the adult population of Bissau, Guinea‐Bissau: a cross‐sectional survey

Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis

Contact Info

Product

Resources

About